SKIN
The Beauty Health Company
Household & Personal Products
Market Cap$121M
5Y Perf.-90.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SKIN vs NUS
Revenue, margins, valuation, and 5-year total return — side by side.
NUS
Nu Skin Enterprises, Inc.
Household & Personal Products
Market Cap$354M
5Y Perf.-85.8%
SKIN vs NUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SKIN | NUS |
|---|---|---|
| Industry | Household & Personal Products | Household & Personal Products |
| Market Cap | $121M | $354M |
| Revenue (TTM) | $301M | $1.56B |
| Net Income (TTM) | $-10M | $110M |
| Gross Margin | 65.3% | 67.2% |
| Operating Margin | -6.9% | -0.7% |
| Forward P/E | — | 7.3x |
| Total Debt | $379M | $282M |
| Cash & Equiv. | $233M | $239M |
SKIN vs NUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SKIN
NUS
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| The Beauty Health C… (SKIN) | 100 | 9.2 | -90.8% |
| Nu Skin Enterprises… (NUS) | 100 | 14.2 | -85.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SKIN vs NUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NUS leads in 5 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. The Beauty Health Company is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
SKIN
The Beauty Health Company
The Growth Play
SKIN is the clearest fit if your priority is growth exposure.
- Rev growth -10.0%, EPS growth 55.6%, 3Y rev CAGR -6.3%
- -10.0% revenue growth vs NUS's -14.3%
- Better valuation composite
Best for: growth exposure
NUS
Nu Skin Enterprises, Inc.
The Income Pick
NUS carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 1.49, yield 3.2%
- -49.1% 10Y total return vs SKIN's -91.4%
- Lower volatility, beta 1.49, Low D/E 35.0%, current ratio 2.08x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SKIN | -10.0% revenue growth vs NUS's -14.3% |
| Value | SKIN | Better valuation composite |
| Quality / Margins | NUS | 7.0% margin vs SKIN's -3.2% |
| Stability / Safety | NUS | Beta 1.49 vs SKIN's 2.00, lower leverage |
| Dividends | NUS | 3.2% yield; the other pay no meaningful dividend |
| Momentum (1Y) | NUS | +31.1% vs SKIN's -11.2% |
| Efficiency (ROA) | NUS | 7.7% ROA vs SKIN's -1.7%, ROIC 5.5% vs -6.8% |
SKIN vs NUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
SKIN vs NUS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNUSLAGGINGSKIN
SKINThe Beauty Health Com…
0leads
NUSNu Skin Enterprises, …
5leads
6 Total Categories
CATEGORYLEADERvs SKINMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NUS4/6
Valuation MetricsMultiples, price ratios, and targets
NUS3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NUS8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NUS6/6
Risk & VolatilityBeta, volatility, and downside exposure
NUS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NUS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NUS is the larger business by revenue, generating $1.6B annually — 5.2x SKIN's $301M. NUS is the more profitable business, keeping 7.0% of every revenue dollar as net income compared to SKIN's -3.2%. On growth, SKIN holds the edge at -1.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SKINThe Beauty Health… | NUSNu Skin Enterpris… |
|---|---|---|
| RevenueTrailing 12 months | $301M | $1.6B |
| EBITDAEarnings before interest/tax | $5M | $45M |
| Net IncomeAfter-tax profit | -$10M | $110M |
| Free Cash FlowCash after capex | $36M | $53M |
| Gross MarginGross profit ÷ Revenue | +65.3% | +67.2% |
| Operating MarginEBIT ÷ Revenue | -6.9% | -0.7% |
| Net MarginNet income ÷ Revenue | -3.2% | +7.0% |
| FCF MarginFCF ÷ Revenue | +12.1% | +3.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | -1.3% | -15.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +23.4% | +100.0% |
NUS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
NUS leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, NUS's 6.0x EV/EBITDA is more attractive than SKIN's 7412.9x.
| Metric | SKINThe Beauty Health… | NUSNu Skin Enterpris… |
|---|---|---|
| Market CapShares × price | $121M | $354M |
| Enterprise ValueMkt cap + debt − cash | $267M | $397M |
| Trailing P/EPrice ÷ TTM EPS | -5.83x | 2.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 7.34x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 7412.86x | 6.04x |
| Price / SalesMarket cap ÷ Revenue | 0.40x | 0.24x |
| Price / BookPrice ÷ Book value/share | 2.07x | 0.46x |
| Price / FCFMarket cap ÷ FCF | 3.25x | 7.69x |
NUS leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
NUS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
NUS delivers a 13.7% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-15 for SKIN. NUS carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs NUS's 6/9, reflecting strong financial health.
| Metric | SKINThe Beauty Health… | NUSNu Skin Enterpris… |
|---|---|---|
| ROE (TTM)Return on equity | -15.4% | +13.7% |
| ROA (TTM)Return on assets | -1.7% | +7.7% |
| ROICReturn on invested capital | -6.8% | +5.5% |
| ROCEReturn on capital employed | -4.5% | +5.7% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 6.20x | 0.35x |
| Net DebtTotal debt minus cash | $146M | $43M |
| Cash & Equiv.Liquid assets | $233M | $239M |
| Total DebtShort + long-term debt | $379M | $282M |
| Interest CoverageEBIT ÷ Interest expense | 0.62x | 8.60x |
NUS leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NUS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUS five years ago would be worth $2,082 today (with dividends reinvested), compared to $726 for SKIN. Over the past 12 months, NUS leads with a +31.1% total return vs SKIN's -11.2%. The 3-year compound annual growth rate (CAGR) favors NUS at -38.1% vs SKIN's -56.0% — a key indicator of consistent wealth creation.
| Metric | SKINThe Beauty Health… | NUSNu Skin Enterpris… |
|---|---|---|
| YTD ReturnYear-to-date | -33.4% | -23.6% |
| 1-Year ReturnPast 12 months | -11.2% | +31.1% |
| 3-Year ReturnCumulative with dividends | -91.5% | -76.3% |
| 5-Year ReturnCumulative with dividends | -92.7% | -79.2% |
| 10-Year ReturnCumulative with dividends | -91.4% | -49.1% |
| CAGR (3Y)Annualised 3-year return | -56.0% | -38.1% |
NUS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
NUS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NUS is the less volatile stock with a 1.49 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NUS currently trades 50.2% from its 52-week high vs SKIN's 34.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SKINThe Beauty Health… | NUSNu Skin Enterpris… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.00x | 1.49x |
| 52-Week HighHighest price in past year | $2.69 | $14.62 |
| 52-Week LowLowest price in past year | $0.76 | $5.63 |
| % of 52W HighCurrent price vs 52-week peak | +34.7% | +50.2% |
| RSI (14)Momentum oscillator 0–100 | 48.3 | 46.1 |
| Avg Volume (50D)Average daily shares traded | 718K | 458K |
NUS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SKIN as "Hold" and NUS as "Hold". Consensus price targets imply 49.9% upside for NUS (target: $11) vs 39.4% for SKIN (target: $1). NUS is the only dividend payer here at 3.21% yield — a key consideration for income-focused portfolios.
| Metric | SKINThe Beauty Health… | NUSNu Skin Enterpris… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $1.30 | $11.00 |
| # AnalystsCovering analysts | 13 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | +3.2% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.24 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.7% |
Insufficient data to determine a leader in this category.
Key Takeaway
NUS leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallNu Skin Enterprises, Inc. (NUS)Leads 5 of 6 categories
Loading custom metrics...
SKIN vs NUS: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is SKIN or NUS a better buy right now?
For growth investors, The Beauty Health Company (SKIN) is the stronger pick with -10.
0% revenue growth year-over-year, versus -14. 3% for Nu Skin Enterprises, Inc. (NUS). Nu Skin Enterprises, Inc. (NUS) offers the better valuation at 2. 3x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate The Beauty Health Company (SKIN) a "Hold" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SKIN or NUS?
Over the past 5 years, Nu Skin Enterprises, Inc.
(NUS) delivered a total return of -79. 2%, compared to -92. 7% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: NUS returned -49. 1% versus SKIN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SKIN or NUS?
By beta (market sensitivity over 5 years), Nu Skin Enterprises, Inc.
(NUS) is the lower-risk stock at 1. 49β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 34% more volatile than NUS relative to the S&P 500. On balance sheet safety, Nu Skin Enterprises, Inc. (NUS) carries a lower debt/equity ratio of 35% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
04Which is growing faster — SKIN or NUS?
By revenue growth (latest reported year), The Beauty Health Company (SKIN) is pulling ahead at -10.
0% versus -14. 3% for Nu Skin Enterprises, Inc. (NUS). On earnings-per-share growth, the picture is similar: Nu Skin Enterprises, Inc. grew EPS 207. 8% year-over-year, compared to 55. 6% for The Beauty Health Company. Over a 3-year CAGR, SKIN leads at -6. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SKIN or NUS?
Nu Skin Enterprises, Inc.
(NUS) is the more profitable company, earning 10. 8% net margin versus -3. 2% for The Beauty Health Company — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUS leads at 4. 4% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — NUS leads at 69. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SKIN or NUS more undervalued right now?
Analyst consensus price targets imply the most upside for NUS: 49.
9% to $11. 00.
07Which pays a better dividend — SKIN or NUS?
In this comparison, NUS (3.
2% yield) pays a dividend. SKIN does not pay a meaningful dividend and should not be held primarily for income.
08Is SKIN or NUS better for a retirement portfolio?
For long-horizon retirement investors, Nu Skin Enterprises, Inc.
(NUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (3. 2% yield). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NUS: -49. 1%, SKIN: -91. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SKIN and NUS?
Both stocks operate in the Consumer Defensive sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SKIN is a small-cap quality compounder stock; NUS is a small-cap deep-value stock. NUS pays a dividend while SKIN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SKIN: -1.3% · NUS: -15.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.